Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.
In highlights from this week's trading diary and posts, Kass offers some advice about fundamentals and about what earnings season means.
Intercept says it received approval from the FDA.
Intercept claims FDA approved the OCA study modifications, but like most pharma companies, no proof was offered, just verbal assurances.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.